

# Dolores Isla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3584578/publications.pdf>

Version: 2024-02-01

129  
papers

15,814  
citations

87723

38  
h-index

16127

124  
g-index

133  
all docs

133  
docs citations

133  
times ranked

16854  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.  | 5.1  | 4,943     |
| 2  | Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.   | 13.9 | 2,213     |
| 3  | A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. <i>Nature</i> , 2008, 452, 638-642.   | 13.7 | 1,399     |
| 4  | Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009, 41, 221-227.   | 9.4  | 572       |
| 5  | Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.  | 0.8  | 445       |
| 6  | Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8636-8645.  | 0.8  | 408       |
| 7  | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.  | 5.1  | 389       |
| 8  | Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.   | 0.8  | 351       |
| 9  | Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 1318-1325.  | 3.2  | 345       |
| 10 | Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. <i>European Respiratory Journal</i> , 2011, 37, 624-631.  | 3.1  | 304       |
| 11 | Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 1160-1168.  | 3.2  | 292       |
| 12 | Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 1194-1203.  | 0.6  | 270       |
| 13 | Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.  | 3.4  | 224       |
| 14 | Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.   | 0.8  | 177       |
| 15 | Replication of Lung Cancer Susceptibility Loci at Chromosomes 15q25, 5p15, and 6p21: A Pooled Analysis From the International Lung Cancer Consortium. <i>Journal of the National Cancer Institute</i> , 2010, 102, 959-971.   | 3.0  | 174       |
| 16 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006, 17, 1205-1212. | 0.6  | 171       |
| 17 | Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.   | 13.9 | 169       |
| 18 | Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2006, 17, 668-675.  | 0.6  | 159       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 64-72.  | 3.2 | 159       |
| 20 | Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. <i>PLoS ONE</i> , 2009, 4, e5133.  | 1.1 | 153       |
| 21 | Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium. <i>European Journal of Cancer</i> , 2012, 48, 1957-1968.   | 1.3 | 143       |
| 22 | Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006, 17, 467-472.  | 0.6 | 117       |
| 23 | CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020, 127, 160-172.                                 | 1.3 | 112       |
| 24 | Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. <i>Journal of Clinical Oncology</i> , 2007, 25, 4736-4742.  | 0.8 | 104       |
| 25 | Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 135.   | 1.8 | 86        |
| 26 | Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway. <i>Clinical Cancer Research</i> , 2006, 12, 7222-7231.   | 3.2 | 84        |
| 27 | Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. <i>Annals of Oncology</i> , 2012, 23, 1111-1120.  | 0.6 | 84        |
| 28 | Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167.                                    | 0.9 | 81        |
| 29 | Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003. | 1.2 | 59        |
| 30 | Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. <i>Thrombosis Research</i> , 2013, 132, 666-670.   | 0.8 | 57        |
| 31 | Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019, 30, 290-296.                                      | 0.6 | 55        |
| 32 | Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.   | 3.4 | 53        |
| 33 | Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. <i>British Journal of Cancer</i> , 2010, 102, 1687-1691.                                  | 2.9 | 52        |
| 34 | Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. <i>Clinical Lung Cancer</i> , 2015, 16, 431-446.   | 1.1 | 48        |
| 35 | Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1071-1077.   | 0.8 | 45        |
| 36 | Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. <i>Journal of Thoracic Disease</i> , 2011, 3, 197-204.   | 0.6 | 44        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198.  | 0.6 | 41        |
| 38 | SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 245-255.  | 1.2 | 41        |
| 39 | Applications of genomics in NSCLC. <i>Lung Cancer</i> , 2005, 50, S33-S40.   | 0.9 | 40        |
| 40 | Platinum Resistance Related to a Functional NER Pathway. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1063-1066.   | 0.5 | 39        |
| 41 | First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2011, 72, 84-91.            | 0.9 | 37        |
| 42 | Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012, 14, 338-349. | 1.2 | 35        |
| 43 | SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1243-1253.   | 1.2 | 34        |
| 44 | Prospective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, 175-183.   | 1.1 | 31        |
| 45 | MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. <i>Lung Cancer</i> , 2012, 76, 373-379.  | 0.9 | 31        |
| 46 | Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 43-49.                   | 1.1 | 31        |
| 47 | Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. <i>Lung Cancer</i> , 2012, 76, 354-361.  | 0.9 | 29        |
| 48 | ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). <i>Journal of Clinical Oncology</i> , 2005, 23, 7002-7002.                    | 0.8 | 29        |
| 49 | Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. <i>Clinical and Translational Oncology</i> , 2011, 13, 460-471.   | 1.2 | 28        |
| 50 | Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.  | 0.6 | 27        |
| 51 | Genome-Wide Significant Association Between a Sequence Variant at 15q15.2 and Lung Cancer Risk. <i>Cancer Research</i> , 2011, 71, 1356-1361.  | 0.4 | 26        |
| 52 | Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study. <i>Lung Cancer</i> , 2013, 81, 84-90.             | 0.9 | 26        |
| 53 | Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 31-38.   | 0.7 | 26        |
| 54 | A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 527-535.  | 1.2 | 26        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Pharmacogenomics and gemcitabine. <i>Annals of Oncology</i> , 2006, 17, v13-v16.   | 0.6 | 25        |
| 56 | Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108.   | 0.9 | 25        |
| 57 | Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.   | 0.9 | 24        |
| 58 | Gemcitabine/Capecitabine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. <i>Clinical Breast Cancer</i> , 2005, 6, 158-162.   | 1.1 | 23        |
| 59 | Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 103-112.  | 1.2 | 23        |
| 60 | Prognostic Value of Serum S-100B in Malignant Melanoma. <i>Tumori</i> , 2004, 90, 607-610.   | 0.6 | 22        |
| 61 | Lung cancer in women: an overview with special focus on Spanish women. <i>Clinical and Translational Oncology</i> , 2014, 16, 517-528.   | 1.2 | 22        |
| 62 | Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients with Cisplatin/Gemcitabine-â€Treated Stage IV Non-â€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 5, 360-365.   | 1.1 | 21        |
| 63 | Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. <i>Npj Precision Oncology</i> , 2020, 4, 15.  | 2.3 | 20        |
| 64 | Lung cancer and treatment in elderly patients: The Achilles Study. <i>Lung Cancer</i> , 2009, 66, 103-106.   | 0.9 | 18        |
| 65 | A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.  | 0.9 | 18        |
| 66 | From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2020, 12, 2974.   | 1.7 | 18        |
| 67 | Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. <i>Lung Cancer</i> , 2021, 153, 25-34. | 0.9 | 17        |
| 68 | Prognostic Significance and Diagnostic Value of Protein S-100 and Tyrosinase in Patients With Malignant Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 335-339.  | 0.6 | 14        |
| 69 | SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289.  | 1.2 | 14        |
| 70 | SEOM clinical guidelines for the treatment of thyroid cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 574-579.  | 1.2 | 14        |
| 71 | Reflexiones sobre la implementaciÃ³n del cribado mediante tomografÃa computarizada de baja dosis en personas con riesgo elevado de padecer cÃncer de pulmÃ³n en EspaÃ±a. <i>Archivos De Bronconeumologia</i> , 2017, 53, 568-573.  | 0.4 | 14        |
| 72 | <i>MDR-1</i> C3435T Genetic Polymorphism and Tobacco-Related Lung Cancer. <i>Oncology</i> , 2003, 64, 183-185.   | 0.9 | 13        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 83-87.  | 0.9 | 13        |
| 74 | Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010, 68, 491-497.  | 0.9 | 13        |
| 75 | SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010). <i>Clinical and Translational Oncology</i> , 2011, 13, 560-564.   | 1.2 | 13        |
| 76 | SEOM clinical guidelines for hereditary cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 580-586.   | 1.2 | 13        |
| 77 | Zoledronic acid in lung cancer with bone metastases: a review. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 421-426.  | 1.1 | 13        |
| 78 | Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?. <i>Cells</i> , 2020, 9, 1525.   | 1.8 | 13        |
| 79 | PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1365.  | 1.0 | 13        |
| 80 | Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. <i>Journal of Medical Economics</i> , 2007, 10, 27-39.  | 1.0 | 12        |
| 81 | Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412.  | 1.1 | 12        |
| 82 | SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). <i>Clinical and Translational Oncology</i> , 2011, 13, 545-551.   | 1.2 | 11        |
| 83 | Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.  | 1.2 | 11        |
| 84 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.   | 3.2 | 11        |
| 85 | Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019, 135, 161-168.   | 0.9 | 10        |
| 86 | Unusual Abdominal and Pelvic Tumors. <i>Journal of Clinical Oncology</i> , 2003, 21, 3540-3541.   | 0.8 | 9         |
| 87 | Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 35-42.  | 1.1 | 9         |
| 88 | SEOM guidelines for the treatment of malignant pleural mesothelioma. <i>Clinical and Translational Oncology</i> , 2011, 13, 569-573.  | 1.2 | 9         |
| 89 | Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. <i>Revista Española De Patología</i> , 2012, 45, 14-28. | 0.6 | 9         |
| 90 | Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017, 35, 358-365.  | 0.6 | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.  | 1.1 | 9         |
| 92  | Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016, 36, 6647-6654.   | 0.5 | 9         |
| 93  | Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 253-261.  | 1.1 | 8         |
| 94  | Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 11-23. | 1.2 | 8         |
| 95  | Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012, 14, 423-429.   | 1.2 | 7         |
| 96  | SEOM clinical guidelines for the treatment of anal cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 525-527.  | 1.2 | 6         |
| 97  | SEOM clinical guidelines for the treatment of invasive bladder cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 552-559.  | 1.2 | 6         |
| 98  | Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019, 28, e12941.   | 0.7 | 6         |
| 99  | The place of targeted therapies in the management of non-small cell bronchial carcinoma. <i>Revue Des Maladies Respiratoires</i> , 2006, 23, 131-136.   | 1.7 | 5         |
| 100 | SEOM clinical guidelines for the treatment of pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 528-535.  | 1.2 | 5         |
| 101 | Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. <i>Clinical and Translational Oncology</i> , 2011, 13, 536-544.  | 1.2 | 5         |
| 102 | SEOM guidelines on thrombosis in cancer patients. <i>Clinical and Translational Oncology</i> , 2011, 13, 592-596.   | 1.2 | 5         |
| 103 | Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, 178-188.e4.   | 1.1 | 5         |
| 104 | Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy. <i>British Journal of Cancer</i> , 2002, 86, 1017-1018.  | 2.9 | 4         |
| 105 | Pharmacogenetics in lung cancer for the lay doctor. <i>Targeted Oncology</i> , 2008, 3, 161-171.  | 1.7 | 4         |
| 106 | Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: A subgroup analysis of the NeoPrevent study. <i>Lung Cancer</i> , 2008, 59, 211-218.  | 0.9 | 4         |
| 107 | Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. <i>Clinical and Translational Oncology</i> , 2009, 11, 428-436.   | 1.2 | 4         |
| 108 | SEOM guidelines: non-seminomatous germ cell cancer (NSGCC). <i>Clinical and Translational Oncology</i> , 2011, 13, 565-568.   | 1.2 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Reflections on the Implementation of Low-dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. Archivos De Bronconeumologia, 2017, 53, 568-573.                                | 0.4 | 4         |
| 110 | Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Clinical and Translational Oncology, 2017, 19, 1537-1542.                                 | 1.2 | 4         |
| 111 | Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical and Translational Oncology, 2021, 23, 1304-1313.                              | 1.2 | 4         |
| 112 | Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clinical and Translational Oncology, 2017, 19, 219-226.  | 1.2 | 3         |
| 113 | Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. Journal of Clinical Oncology, 2012, 30, e12012-e12012.   | 0.8 | 3         |
| 114 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer, 2022, 166, 107-113. | 0.9 | 3         |
| 115 | SEOM clinical guidelines for the treatment of oesophageal cancer. Clinical and Translational Oncology, 2011, 13, 520-524.  | 1.2 | 2         |
| 116 | &lt;em&gt;nab&lt;/em&gt;-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Lung Cancer: Targets and Therapy, 2017, Volume 8, 207-216.                      | 1.3 | 2         |
| 117 | Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. Clinical and Translational Oncology, 2012, 14, 820-826.                    | 1.2 | 1         |
| 118 | P3-095: Erlotinib in advanced squamous cell carcinoma of the lung. Journal of Thoracic Oncology, 2007, 2, S719.  | 0.5 | 1         |
| 119 | Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials. Journal of Clinical Oncology, 2007, 25, 7679-7679.                                  | 0.8 | 1         |
| 120 | Lung cancer in women: The Spanish female-specific database WORLD 07. Journal of Clinical Oncology, 2009, 27, 8084-8084.  | 0.8 | 1         |
| 121 | Never-smoking women with lung cancer from the Spanish WORLD07 database.. Journal of Clinical Oncology, 2012, 30, 1531-1531.  | 0.8 | 1         |
| 122 | Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. Journal of Clinical Oncology, 2012, 30, e12000-e12000.   | 0.8 | 1         |
| 123 | Desmoplastic small round cell tumor of the abdomen. Oncologia, 2006, 29, .   | 0.0 | 1         |
| 124 | Radiation pneumonitis after local-regional radiotherapy following autologous stem-cell transplant for high-risk breast cancer. Annals of Oncology, 1999, 10, 1529.   | 0.6 | 0         |
| 125 | SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology, 2011, 13, 587-591.   | 1.2 | 0         |
| 126 | In answer to: â€œComments to SEOM clinical guidelines for the treatment of thyroid cancerâ€•by Garcilaso Riesco-Eizaguirre et al. Clinical and Translational Oncology, 2012, 14, 711-712.                        | 1.2 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. BMC Psychology, 2020, 8, 123. | 0.9 | 0         |
| 128 | Prognostic value of quantitative immune alterations in melanoma patients. Oncologia, 2006, 29, .   | 0.0 | 0         |
| 129 | Outcomes of real-world CANTABRICO trial match results from CASPIAN. , 0, , .   |     | 0         |